Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 19, 2026 saying it no longer meets the $15,000,000 minimum market value of publicly held shares (MVPHS) requirement under Nasdaq Rule 5450(b). The notice imposes a 180-calendar-day cure period ending Aug 18, 2026, during which the company must exceed $15,000,000 MVPHS for at least 10 consecutive business days to regain compliance. ADSs continue trading on the Nasdaq Global Select Market while the company evaluates options, including restoring market value, seeking transfer to The Nasdaq Capital Market if eligible, or appealing any delisting determination.

Positive

• ADSs continue trading on Nasdaq Global Select Market
• Company has a 180-calendar-day cure period ending August 18, 2026
• Can regain compliance by exceeding $15,000,000 MVPHS for 10 business days
• Company may appeal any delisting determination to a Nasdaq hearings panel

Negative

• MVPHS fell below the required $15,000,000 threshold
• Risk of delisting if compliance not restored by August 18, 2026
• Possible forced transfer to The Nasdaq Capital Market if deficiency continues
• Uncertainty over success of any appeal to Nasdaq hearings panel

Key Figures

MVPHS threshold: $15,000,000 MVPHS review window: 30 consecutive business days Compliance period: 180 calendar days +2 more

5 metrics

MVPHS threshold $15,000,000 Minimum market value of publicly held shares required under Nasdaq Rule 5450(b)

MVPHS review window 30 consecutive business days Period over which Nasdaq determined MVPHS deficiency

Compliance period 180 calendar days Time until <b>August 18, 2026</b> to regain MVPHS compliance

Compliance window 10 consecutive business days Required period MVPHS must exceed $15,000,000 to regain compliance

Compliance deadline August 18, 2026 Deadline for regaining MVPHS compliance or transferring listing

Market Reality Check

Price: $0.7433 Vol: Volume 89,224 vs 20-day a...

low vol

$0.7433 Last Close

Volume Volume 89,224 vs 20-day average 271,541 suggests muted trading ahead of this notice. low

Technical Shares at 0.7121 are trading below the 200-day MA 0.92 and about 79.3% under the 52-week high.

Peers on Argus

TRIB was down about 2.06% while peers showed mixed moves: IRIX down, NSYS flat-t...

2 Up 1 Down

TRIB was down about 2.06% while peers showed mixed moves: IRIX down, NSYS flat-to-up, AIMD up 6.25%, and PTHL up sharply 113.16%. Momentum scanner flagged AIMD and MYO up, VVOS down, reinforcing that TRIB’s pressure is stock-specific rather than a broad Medical Devices move.

Historical Context

5 past events · Latest: Feb 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 13	Nasdaq bid non-compliance	Negative	-0.6%	Nasdaq notice on ADS bid price falling below $1.00 for 30 days.
Feb 10	Regulatory manufacturing approval	Positive	+8.8%	Final approval to begin offshored upstream Uni‑Gold HIV manufacturing.
Feb 10	Product recognition award	Positive	+8.8%	Premier Hb9210 HbA1c analyser receives IFCC Gold Classification for 2026.
Dec 23	Capital structure agreements	Positive	+43.5%	New term loan and equitization capacity to strengthen liquidity and extend runway.
Dec 23	Major HIV test order	Positive	+43.5%	9 million-unit TrinScreen HIV order plus stronger Q3 2025 financial metrics.

Pattern Detected

News-driven moves generally align with tone: operational and financing positives saw strong gains, while Nasdaq non-compliance notices saw mild negative reactions.

Recent Company History

Over recent months, Trinity Biotech has mixed operational progress with listing and capital-structure challenges. On Dec 23, 2025, it announced capital structure agreements and a major 9 million-unit TrinScreen HIV order, both followed by +43.5% moves. On Feb 10, 2026, regulatory approval for offshored Uni-Gold™ HIV manufacturing and IFCC Gold Classification for its Hb9210™ analyser each coincided with +8.75% reactions. By Feb 13, 2026, however, a Nasdaq minimum bid price non-compliance notice produced a modest -0.64% move, framing today’s new MVPHS deficiency notice within a pattern of listing pressures.

Market Pulse Summary

This announcement adds a second Nasdaq deficiency, this time tied to the $15,000,000 market value of...

Analysis

This announcement adds a second Nasdaq deficiency, this time tied to the $15,000,000 market value of publicly held shares requirement, alongside the earlier minimum bid price issue. The company has 180 days, until August 18, 2026, to cure the MVPHS shortfall, with options including transfer to the Nasdaq Capital Market or appealing a delisting notice. Investors may monitor progress on compliance, operational execution from recent HIV and diabetes initiatives, and any further regulatory updates.

Key Terms

nasdaq global select market, market value of publicly held shares, nasdaq capital market, delisting

4 terms

nasdaq global select market regulatory

"which will continue to trade at this time on the Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

market value of publicly held shares financial

"maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

nasdaq capital market regulatory

"may seek to apply for a transfer to The Nasdaq Capital Market exchange"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

delisting regulatory

"Nasdaq will provide written notification to the Company that its ADSs are subject to delisting"

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

AI-generated analysis. Not financial advice.

DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq’s review of the Company’s MVPHS for the last 30 consecutive business days.

This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days, or until August 18, 2026, to regain compliance with the MVPHS requirement. To regain compliance, the Company’s MVPHS must exceed $15,000,000 for a minimum of 10 consecutive business days. In the event that the deficiency continues for 180 days, the Company may seek to apply for a transfer to The Nasdaq Capital Market exchange if it meets the requirements for continued listing thereon. If the Company does not regain compliance with the minimum MVPHS requirement by August 18, 2026 or transfer to The Nasdaq Capital Market, Nasdaq will provide written notification to the Company that its ADSs are subject to delisting. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.

Forward-Looking Statements

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Contact:

Trinity Biotech plc Paul Murphy (353)-1-2769800

RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com

FAQ

What notice did Trinity Biotech (TRIB) receive from Nasdaq on February 19, 2026?

The company received a notice that its publicly held market value is below the $15,000,000 Nasdaq requirement. According to the company, Nasdaq’s review found TRIB did not meet Rule 5450(b) based on the last 30 consecutive business days, triggering a compliance cure period.

How long does Trinity Biotech (TRIB) have to regain Nasdaq MVPHS compliance?

TRIB has 180 calendar days to regain compliance, until August 18, 2026. According to the company, MVPHS must exceed $15,000,000 for at least 10 consecutive business days within that period to satisfy Nasdaq requirements and avoid delisting.

What happens if Trinity Biotech (TRIB) does not meet the $15,000,000 MVPHS by August 18, 2026?

If TRIB fails to regain compliance by that date, Nasdaq may issue a delisting notice unless the company transfers to The Nasdaq Capital Market. According to the company, transfer is an option if listing requirements for that market are met.

Can Trinity Biotech (TRIB) appeal a Nasdaq delisting decision?

Yes, the company may appeal any delisting determination to a Nasdaq hearings panel. According to the company, an appeal follows Nasdaq procedures, but there is no assurance an appeal would be successful in preventing delisting.

Do Trinity Biotech ADSs stop trading after the Nasdaq notice for MVPHS deficiency?

No, the notice has no immediate effect on trading; ADSs continue to trade on Nasdaq Global Select Market. According to the company, trading will continue while the 180-day cure period proceeds and options are evaluated.